NewGenIvf Group Limited (NASDAQ:NIVF) Short Interest Update

NewGenIvf Group Limited (NASDAQ:NIVF) saw a large drop in short interest in December. As of December 31st, there was short interest totaling 13,899 shares, a drop of 93.8% from the December 15th total of 223,462 shares. Based on an average daily volume of 225,239 shares, the days-to-cover ratio is presently 0.1 days. Currently, 3.4% of the shares of the company are sold short. Currently, 3.4% of the shares of the company are sold short. Based on an average daily volume of 225,239 shares, the days-to-cover ratio is presently 0.1 days.

NewGenIvf Group Price Performance

Shares of NewGenIvf Group stock traded down $0.02 during midday trading on Monday, hitting $0.58. 131,985 shares of the company were exchanged, compared to its average volume of 197,108. The firm has a 50 day simple moving average of $1.37 and a 200-day simple moving average of $7.59. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.43 and a quick ratio of 3.37. NewGenIvf Group has a 52 week low of $0.56 and a 52 week high of $1,907.50.

Analysts Set New Price Targets

A number of research analysts recently commented on NIVF shares. Weiss Ratings restated a “sell (d)” rating on shares of NewGenIvf Group in a research note on Friday, October 31st. Wall Street Zen upgraded shares of NewGenIvf Group to a “hold” rating in a research note on Saturday, December 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, NewGenIvf Group has an average rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.